A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY OF NEOADJUVANT-ADJUVANT DURVALUMAB AND FLOT CHEMOTHERAPY FOLLOWED BY ADJUVANT DURVALUMAB IN PATIENTS WITH RESECTABLE GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER (GC/GEJC) (MATTERHORN)

Registry ID

D910GC00001

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

ASTRAZENECA CANADA INC

Start date

2021-07-27

Last update

2020-09-18

Conditions

• GASTROESOPHAGEAL JUNCTION CANCER

Related clinical trials

• ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
• A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05)
• A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977)
• A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
• A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
• A PHASE 1B/3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY AND NIVOLUMAB VERSUS CHEMOTHERAPY AND NIVOLUMAB ALONE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE 102)

View on source registry